11results about How to "Low immunogenicity" patented technology

The application provides an antibody against B7H6 and application thereof, the antibody comprising heavy chain variable region CDR1, CDR2 and CDR3 sequences shown in the amino acid sequences of SEQ ID NO: 1, 2 and 3 respectively or having at least 95% identity with SEQ ID NO: 1, 2 and 3; and / or light chain variable region CDR1, CDR2 and CDR3 sequences shown in the amino acid sequences of SEQ ID NO: 4, 5 and 6 respectively or having at least 95% identity with 4, 5 and 6. The antibody of the embodiment of the application can be combined with human and monkey B7H6 proteins, and the bispecific antibody prepared by using the antibody has higher human and monkey B7H6 binding activity, and can effectively treat and / or prevent B7H6-mediated related diseases.

This invention belongs to the field of biotechnology, specifically relating to a high-affinity anti-tumor NK cell, its preparation method, and its application. This invention designs NK92 cells transfected with a haPD1 high-affinity chimeric conversion receptor, wherein the high-affinity chimeric conversion receptor includes the extracellular segment of haPD-1, the transmembrane segment of CD28, the intracellular segment of DAP10, and the intracellular segment of CD3ζ. This invention prepares haChR3-NK92 cells through the construction of a recombinant lentiviral vector, lentiviral packaging, and lentiviral transfection of NK92 cells. In this invention, haPD-1 serves as the extracellular recognition domain of the CAR structure, specifically binding to PD-L1 on tumor cells to achieve a stronger tumor-killing effect. The co-stimulatory molecule CD28 serves as the transmembrane region to transmit extracellular information into the cell, integrating the adaptor protein DAP10 of the NK cell surface activator receptor NKG2D into the cell, and further embedding the intracellular segment CD3ζ commonly used in CAR design to jointly promote NK cell activation. The preparation method of this invention can successfully construct haChR3-NK92 cells, achieve the expression of the target plasmid, and be applied in anti-tumor drug research.

This invention relates to the field of biomedical technology, and more particularly to a PD-L1-targeting polypeptide, its conjugate, and its applications. The polypeptide possesses the amino acid sequence shown in SEQ ID NO.1 or SEQ ID NO.2. This invention de novo designs a high-affinity PD-L1-targeting specific polypeptide. This polypeptide achieves extremely high affinity with the extracellular domain of the PD-L1 protein through its unique spatial conformation, exhibiting excellent targeting and recognition capabilities. The polypeptide provided by this invention can be conjugated with various modified molecules, such as radionuclides, and the constructed molecular imaging probe exhibits excellent tumor tissue targeting and enrichment capabilities, superior biocompatibility, and clear imaging contrast, enabling specific recognition of PD-L1-positive tumor lesions. It can be applied to clinical scenarios such as early precision diagnosis of tumors, screening of patients for immunotherapy, real-time monitoring of efficacy, and prognostic assessment, possessing significant translational medical value and broad application prospects.

This invention discloses a nanobody Nb.TB1, engineered plant exosomes, their preparation methods, and applications, belonging to the field of biomedical technology. The amino acid sequence of the nanobody Nb.TB1 is shown in Seq ID No. 1. Furthermore, this invention proposes a method for preparing engineered plant exosomes, comprising the following steps: S1, extraction of Gastrodia elata exosomes: extracting Gastrodia elata exosomes from Gastrodia elata using an enzymatic method; S2, expression and purification of the blood-brain barrier-crossing nanobody fusion protein with Sortase A ligase; S3, surface modification of the Gastrodia elata exosomes. In addition, this invention also proposes an engineered plant exosome prepared by the above method. Furthermore, this invention proposes the application of the above-mentioned engineered plant exosomes in the preparation of targeted therapeutic drugs for central nervous system diseases. The engineered plant exosomes prepared by this invention exhibit high blood-brain barrier crossing efficiency.

This disclosure pertains to the field of biomedicine, specifically relating to double-stranded oligonucleotides targeting the APP gene and their applications. Specifically, it provides double-stranded oligonucleotide agents or their salts, conjugates, or compositions for inhibiting amyloid precursor protein (APP) expression, wherein the double-stranded oligonucleotide agent comprises a sense strand and an antisense strand forming a double-stranded region; wherein the antisense strand sequence comprises at least 15 consecutive nucleotides of any of the sequences shown in SEQ ID NO:1-154 with a difference of no more than 3 nucleotides, and / or the sense strand sequence comprises at least 15 consecutive nucleotides of any of the sequences shown in SEQ ID NO:155-308 with a difference of no more than 3 nucleotides. The double-stranded oligonucleotide agent or its salt for inhibiting APP expression disclosed in this application can significantly inhibit APP expression and can be used for the prevention and / or treatment of diseases or conditions mediated by the APP gene and / or associated with protein amyloidosis.

This invention provides an aptamer targeting the growth hormone receptor and its uses, the nucleotide sequence of which is shown in SEQ ID NO.1 or SEQ ID NO.2. This invention utilizes a modified SELEX technique to perform multiple rounds of screening targeting recombinant GHR protein, obtaining specific nucleic acid aptamers with high affinity for GHR (KD values ​​at the micromolar level). In vivo distribution experiments show that the fluorescently labeled aptamer can efficiently and specifically accumulate in white adipose tissue (including inguinal and gonadal fat) at the in vivo level, exhibiting excellent tissue targeting. The nucleic acid aptamer and its derivatives of this invention can be used to prepare drugs or diagnostic reagents targeting adipose tissue, for example, for the prevention or treatment of metabolic diseases such as obesity, type 2 diabetes, fatty liver, hyperlipidemia, or cardiovascular disease.

This invention discloses a collagen-based anti-corrosion coating with tissue repair properties, its preparation method, and its applications, belonging to the field of medical coating technology. This invention designs a novel self-healing anti-corrosion coating and loads collagen onto the coating using excipients, achieving a deep integration of anti-corrosion protection and biological function. The prepared collagen-based anti-corrosion coating is firmly bonded to a magnesium alloy substrate via covalent bonds. After 4 weeks of in vivo implantation, no cracking or detachment was observed, the stent structure maintained good integrity, and it provides continuous radial support, offering sufficient time for vascular repair. This provides a feasible solution for the clinical translation of next-generation biodegradable magnesium-based vascular stents.

This invention provides a nucleic acid aptamer that binds to the Spike protein of the novel coronavirus SARS-CoV-2 and its applications. The nucleic acid aptamer includes the nucleotide sequence shown in SEQ ID NO 1, 2, or 3; the nucleic acid aptamer, its combinations, and derivatives can specifically bind to the Spike protein of SARS-CoV-2 (wild-type or mutant), blocking the interaction between the Spike protein and the TLR4 protein, and inhibiting the inflammatory response triggered by SARS-CoV-2 virus infection; it has advantages such as high affinity, strong stability, small molecular weight, and low immunogenicity; this invention can be applied in the fields of detection, labeling, imaging, diagnosis, and treatment of the novel coronavirus.

This invention provides a high-throughput and efficient method for screening multiple target genes that can regulate mRNA expression levels in cells by co-transfecting or sequentially transfecting mRNA with a gene silencing library targeting genes in cells using lipid nanoparticles. Several target genes that can regulate mRNA protein expression levels through the action of siRNA have been discovered. By manipulating these genes that regulate mRNA expression levels, the translational capacity of mRNA in mRNA vaccine and drug development can be improved, mRNA protein expression efficiency can be increased, and immunogenicity and toxicity can be reduced.

This invention provides an in vitro packaging method for ring virus pseudovirus particles, belonging to the field of molecular biology technology. The method involves eukaryotic expression of a ring virus capsid expression plasmid. Ring virus pseudovirus particles can serve as a safe and efficient novel viral vector for gene therapy and basic research. The technical method of this invention will promote basic research on ring viruses and related vector-based applications.